Publication | Closed Access

Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study

Disease PsychosisAlzheimer's DiseasePsychiatryDementiaPimavanserin Versus PlaceboTreatment EvaluationVascular DementiaNeuropsychiatryNeurologyAging-associated DiseasePhase 2MedicineTreatmentHealth Sciences